Therapeutic Effect of Irbesartan, AVAPRO, on Blood Pressure and eGFR by Morning or Bedtime Administration in Chronic Kidney Disease Patients(ABPM-CKD)
Not Applicable
- Conditions
- Chronic Kidney Disease
- Registration Number
- JPRN-UMIN000006686
- Lead Sponsor
- Department of Nephrology, Nagoya university graduate school of medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
Not provided
Exclusion Criteria
1)Pregant or possible pregnant patients 2)Patients with bilareral renal artery stenosis and patients with unilateral and renal artery stenosis 3)Nephrotic syndrome 4)Patients whose hepatic function was over 2 times higher than normal upper limit within eight weekss before the informed consent acquisition 5)Patients received hospitalizing by onset of cardiovascular disease, myocardial infarction, cerebral apoplexy, cardiac insufficiency within eight weeks before the informed consent acquisition 6)Allergic reaction to irbesartan 7)Judged inappropriate for this study by the physicians
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 1.Change of blood pressure (a:Office Blood pressure, b:Self-monitoring at home, c: ABPM)
- Secondary Outcome Measures
Name Time Method 1.eGFR 2.Serum creatinine 3.Uric acid 4.Plasma renin activity 5.Plasma aldosterone 6.Urinary sodium concentration (daytime, sleeping time) 7. Albumin creatinine ratio of spot urine